CoChat

Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease

Schlepckow, Kai, Morenas-Rodríguez, Estrella, Hong, Soyon, Haass, Christian · 2023 · The Lancet Neurology
Cited by 114

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Neurodegenerative disorders, including Alzheimer's disease, are associated with microgliosis. Microglia have long been considered to have detrimental roles in Alzheimer's disease. However, functional analyses of genes encoding risk factors that are linked to late-onset Alzheimer's disease, and that are enriched or exclusively expressed in microglia, have revealed unexpected protective functions. One of the major risk genes for Alzheimer's disease is TREM2. Risk variants of TREM2 are loss-of-function mutations affecting chemotaxis, phagocytosis, lipid and energy metabolism, and survival and proliferation. Agonistic anti-TREM2 antibodies have been developed to boost these protective functions in patients with intact TREM2 alleles. Several anti-TREM2 antibodies are in early clinical trials, and current efforts aim to achieve more efficient transport of these antibodies across the blood-brain barrier. PET imaging could be used to monitor target engagement. Data from animal models, and biomarker studies in patients, further support a rationale for boosting TREM2 functions during the preclinical stage of Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(23)00247-8

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 114

Metadata

Authors
Schlepckow, K., Morenas-Rodríguez, E., Hong, S., & Haass, C.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2023-11
Volume
22
Issue
11
Pages
1048-1060
ISSN
1474-4422 (ISSN-L)
OpenAlex
W4387761639
Cited by
114
References
62
FWCI
9.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease. https://app.cochat.ai/papers/10.1016/s1474-4422(23)00247-8
The paper
Schlepckow, K., Morenas-Rodríguez, E., Hong, S., & Haass, C. (2023). Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(23)00247-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.